Patient Recruitment for CNS Trials: Understanding patient Perspectives: Understanding Patient Perspectives
Central Nervous System (CNS) disorders affect millions worldwide, spanning all ages and demographics, and a wide variety of indications from behavioral to neurodegenerative. Clinical trial activity in neurology and psychology continue to rise, driven by the growing prevalence of CNS conditions and the urgent need for innovative treatments in a diverse array of indications. This research significant progress in the effort to understand and address the complexities of CNS conditions.
Key areas of focus include neurodegenerative diseases like Alzheimer’s and Parkinson’s, psychiatric disorders such as depression and schizophrenia, and chronic conditions like multiple sclerosis, epilepsy, and chronic pain syndromes. These studies aim to improve treatment efficacy and enhance the quality of life for individuals living with CNS conditions.
Eating disorders can affect individuals of all ages but most commonly emerge during adolescence and young adulthood. They are more frequently diagnosed in females, though they also impact males and may be underdiagnosed in marginalized groups. Socioeconomic factors influence access to treatment, and cultural pressures, social media exposure, and lifestyle habits such as dieting or excessive exercise can contribute to their development and severity.
Multiple Sclerosis (MS) is typically diagnosed between the ages of 20 and 40, though it can occur at any age. Women are two to three times more likely than men to develop the condition, and it affects all racial and ethnic groups, but it is most common among individuals of Northern European descent. Black patients, particularly Black women, may experience more severe disease progression. Environmental factors, including geographic location and vitamin D levels, may contribute to risk, while socioeconomic status and access to healthcare can influence diagnosis, treatment, and overall disease management.
Alzheimer’s disease primarily affects older adults, with the majority of cases diagnosed in individuals over 65, though early-onset Alzheimer’s can occur as early as the 40s or 50s. Women are disproportionately affected, both because they live longer and due to potential biological differences in disease progression. While Alzheimer’s occurs across all racial and ethnic groups, Black and Hispanic individuals have a higher risk compared to White individuals, partly due to disparities in healthcare access, socioeconomic factors, and higher rates of comorbid conditions like cardiovascular disease. Genetics play a key role, especially in early-onset cases, while lifestyle factors such as diet, exercise, and cognitive engagement may influence disease development and progression.
Despite the availability of effective treatments and management options for Central Nervous System conditions, barriers such as stigma, limited awareness of trial opportunities, a preference for familiar healthcare providers, or environmental challenges can deter patients from exploring clinical research as a care pathway.
Recruiting participants for CNS clinical trials can be challenging, but Direct-to-Patient Recruitment offers an effective solution to reach this diverse and often underserved population.
Central Nervous System indications such as those that contain symptom-based descriptions or recent diagnoses are frequently researched online by patients and caregivers looking for information on treatment options, symptom management, and emerging therapies. This creates an opportunity to leverage advanced targeting and screening tools to deliver clinical trial opportunities directly to individuals seeking innovative alternatives to traditional healthcare pathways.
This approach not only increases awareness about available trials but also empowers patients and caregivers to consider personalized solutions tailored to their unique medical profiles, ultimately connecting them with studies aligned with their specific needs and conditions.
Patients Randomized
Enrollment Timelines
Enrollment Rate
AutoCruitment’s patient recruitment platform supports Sponsors, CRO Partners and Research Sites by decreasing time, risk and cost to bring new therapies to market.
